Functionally active Fc mutant antibodies recognizing cancer antigens generated rapidly at high yields

Kristina M. Ilieva, Judit Fazekas-Singer, Daniela Y. Achkova, Tihomir S. Dodev, Silvia Mele, Silvia Crescioli, Heather J. Bax, Anthony Cheung, Panagiotis Karagiannis, Isabel Correa, Mariangela Figini, Rebecca Marlow, Debra H. Josephs, Andrew J. Beavil, John Maher, James F. Spicer, Erika Jensen-Jarolim, Andrew N. Tutt, Sophia N. Karagiannis

Research output: Contribution to journalArticle

Abstract

Monoclonal antibodies find broad application as therapy for various types of cancer by employing multiple mechanisms of action against tumors. Manipulating the Fc-mediated functions of antibodies that engage immune effector cells, such as NK cells, represents a strategy to influence effector cell activation and to enhance antibody potency and potentially efficacy. We developed a novel approach to generate and ascertain the functional attributes of Fc mutant monoclonal antibodies. This entailed coupling single expression vector (pVitro1) antibody cloning, using polymerase incomplete primer extension (PIPE) polymerase chain reaction, together with simultaneous Fc region point mutagenesis and high yield transient expression in human mammalian cells. Employing this, we engineered wild type, low (N297Q, NQ), and high (S239D/I332E, DE) FcR-binding Fc mutant monoclonal antibody panels recognizing two cancer antigens, HER2/neu and chondroitin sulfate proteoglycan 4. Antibodies were generated with universal mutagenic primers applicable to any IgG1 pVitro1 constructs, with high mutagenesis and transfection efficiency, in small culture volumes, at high yields and within 12 days from design to purified material. Antibody variants conserved their Fab-mediated recognition of target antigens and their direct anti-proliferative effects against cancer cells. Fc mutations had a significant impact on antibody interactions with Fc receptors (FcRs) on human NK cells, and consequently on the potency of NK cell activation, quantified by immune complex-mediated calcium mobilization and by antibody-dependent cellular cytotoxicity (ADCC) of tumor cells. This strategy for manipulation and testing of Fc region engagement with cognate FcRs can facilitate the design of antibodies with defined effector functions and potentially enhanced efficacy against tumor cells.

Original languageEnglish
Article number1112
JournalFrontiers in Immunology
Volume8
Issue numberSEP
DOIs
Publication statusPublished - Sep 11 2017

Fingerprint

Antigens
Antibodies
Neoplasms
Natural Killer Cells
Fc Receptors
Monoclonal Antibodies
Mutagenesis
Antigen-Antibody Complex
Transfection
Organism Cloning
Immunoglobulin G
Calcium
Polymerase Chain Reaction
Mutation
Therapeutics

Keywords

  • ADCC
  • Antibodies
  • Cancer immunotherapy
  • Chondroitin sulfate proteoglycan 4
  • Cloning
  • Expression
  • HER2
  • Mutants

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Ilieva, K. M., Fazekas-Singer, J., Achkova, D. Y., Dodev, T. S., Mele, S., Crescioli, S., ... Karagiannis, S. N. (2017). Functionally active Fc mutant antibodies recognizing cancer antigens generated rapidly at high yields. Frontiers in Immunology, 8(SEP), [1112]. https://doi.org/10.3389/fimmu.2017.01112

Functionally active Fc mutant antibodies recognizing cancer antigens generated rapidly at high yields. / Ilieva, Kristina M.; Fazekas-Singer, Judit; Achkova, Daniela Y.; Dodev, Tihomir S.; Mele, Silvia; Crescioli, Silvia; Bax, Heather J.; Cheung, Anthony; Karagiannis, Panagiotis; Correa, Isabel; Figini, Mariangela; Marlow, Rebecca; Josephs, Debra H.; Beavil, Andrew J.; Maher, John; Spicer, James F.; Jensen-Jarolim, Erika; Tutt, Andrew N.; Karagiannis, Sophia N.

In: Frontiers in Immunology, Vol. 8, No. SEP, 1112, 11.09.2017.

Research output: Contribution to journalArticle

Ilieva, KM, Fazekas-Singer, J, Achkova, DY, Dodev, TS, Mele, S, Crescioli, S, Bax, HJ, Cheung, A, Karagiannis, P, Correa, I, Figini, M, Marlow, R, Josephs, DH, Beavil, AJ, Maher, J, Spicer, JF, Jensen-Jarolim, E, Tutt, AN & Karagiannis, SN 2017, 'Functionally active Fc mutant antibodies recognizing cancer antigens generated rapidly at high yields', Frontiers in Immunology, vol. 8, no. SEP, 1112. https://doi.org/10.3389/fimmu.2017.01112
Ilieva, Kristina M. ; Fazekas-Singer, Judit ; Achkova, Daniela Y. ; Dodev, Tihomir S. ; Mele, Silvia ; Crescioli, Silvia ; Bax, Heather J. ; Cheung, Anthony ; Karagiannis, Panagiotis ; Correa, Isabel ; Figini, Mariangela ; Marlow, Rebecca ; Josephs, Debra H. ; Beavil, Andrew J. ; Maher, John ; Spicer, James F. ; Jensen-Jarolim, Erika ; Tutt, Andrew N. ; Karagiannis, Sophia N. / Functionally active Fc mutant antibodies recognizing cancer antigens generated rapidly at high yields. In: Frontiers in Immunology. 2017 ; Vol. 8, No. SEP.
@article{cc932fe5a09f429ead08aac2ec4854da,
title = "Functionally active Fc mutant antibodies recognizing cancer antigens generated rapidly at high yields",
abstract = "Monoclonal antibodies find broad application as therapy for various types of cancer by employing multiple mechanisms of action against tumors. Manipulating the Fc-mediated functions of antibodies that engage immune effector cells, such as NK cells, represents a strategy to influence effector cell activation and to enhance antibody potency and potentially efficacy. We developed a novel approach to generate and ascertain the functional attributes of Fc mutant monoclonal antibodies. This entailed coupling single expression vector (pVitro1) antibody cloning, using polymerase incomplete primer extension (PIPE) polymerase chain reaction, together with simultaneous Fc region point mutagenesis and high yield transient expression in human mammalian cells. Employing this, we engineered wild type, low (N297Q, NQ), and high (S239D/I332E, DE) FcR-binding Fc mutant monoclonal antibody panels recognizing two cancer antigens, HER2/neu and chondroitin sulfate proteoglycan 4. Antibodies were generated with universal mutagenic primers applicable to any IgG1 pVitro1 constructs, with high mutagenesis and transfection efficiency, in small culture volumes, at high yields and within 12 days from design to purified material. Antibody variants conserved their Fab-mediated recognition of target antigens and their direct anti-proliferative effects against cancer cells. Fc mutations had a significant impact on antibody interactions with Fc receptors (FcRs) on human NK cells, and consequently on the potency of NK cell activation, quantified by immune complex-mediated calcium mobilization and by antibody-dependent cellular cytotoxicity (ADCC) of tumor cells. This strategy for manipulation and testing of Fc region engagement with cognate FcRs can facilitate the design of antibodies with defined effector functions and potentially enhanced efficacy against tumor cells.",
keywords = "ADCC, Antibodies, Cancer immunotherapy, Chondroitin sulfate proteoglycan 4, Cloning, Expression, HER2, Mutants",
author = "Ilieva, {Kristina M.} and Judit Fazekas-Singer and Achkova, {Daniela Y.} and Dodev, {Tihomir S.} and Silvia Mele and Silvia Crescioli and Bax, {Heather J.} and Anthony Cheung and Panagiotis Karagiannis and Isabel Correa and Mariangela Figini and Rebecca Marlow and Josephs, {Debra H.} and Beavil, {Andrew J.} and John Maher and Spicer, {James F.} and Erika Jensen-Jarolim and Tutt, {Andrew N.} and Karagiannis, {Sophia N.}",
year = "2017",
month = "9",
day = "11",
doi = "10.3389/fimmu.2017.01112",
language = "English",
volume = "8",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",
number = "SEP",

}

TY - JOUR

T1 - Functionally active Fc mutant antibodies recognizing cancer antigens generated rapidly at high yields

AU - Ilieva, Kristina M.

AU - Fazekas-Singer, Judit

AU - Achkova, Daniela Y.

AU - Dodev, Tihomir S.

AU - Mele, Silvia

AU - Crescioli, Silvia

AU - Bax, Heather J.

AU - Cheung, Anthony

AU - Karagiannis, Panagiotis

AU - Correa, Isabel

AU - Figini, Mariangela

AU - Marlow, Rebecca

AU - Josephs, Debra H.

AU - Beavil, Andrew J.

AU - Maher, John

AU - Spicer, James F.

AU - Jensen-Jarolim, Erika

AU - Tutt, Andrew N.

AU - Karagiannis, Sophia N.

PY - 2017/9/11

Y1 - 2017/9/11

N2 - Monoclonal antibodies find broad application as therapy for various types of cancer by employing multiple mechanisms of action against tumors. Manipulating the Fc-mediated functions of antibodies that engage immune effector cells, such as NK cells, represents a strategy to influence effector cell activation and to enhance antibody potency and potentially efficacy. We developed a novel approach to generate and ascertain the functional attributes of Fc mutant monoclonal antibodies. This entailed coupling single expression vector (pVitro1) antibody cloning, using polymerase incomplete primer extension (PIPE) polymerase chain reaction, together with simultaneous Fc region point mutagenesis and high yield transient expression in human mammalian cells. Employing this, we engineered wild type, low (N297Q, NQ), and high (S239D/I332E, DE) FcR-binding Fc mutant monoclonal antibody panels recognizing two cancer antigens, HER2/neu and chondroitin sulfate proteoglycan 4. Antibodies were generated with universal mutagenic primers applicable to any IgG1 pVitro1 constructs, with high mutagenesis and transfection efficiency, in small culture volumes, at high yields and within 12 days from design to purified material. Antibody variants conserved their Fab-mediated recognition of target antigens and their direct anti-proliferative effects against cancer cells. Fc mutations had a significant impact on antibody interactions with Fc receptors (FcRs) on human NK cells, and consequently on the potency of NK cell activation, quantified by immune complex-mediated calcium mobilization and by antibody-dependent cellular cytotoxicity (ADCC) of tumor cells. This strategy for manipulation and testing of Fc region engagement with cognate FcRs can facilitate the design of antibodies with defined effector functions and potentially enhanced efficacy against tumor cells.

AB - Monoclonal antibodies find broad application as therapy for various types of cancer by employing multiple mechanisms of action against tumors. Manipulating the Fc-mediated functions of antibodies that engage immune effector cells, such as NK cells, represents a strategy to influence effector cell activation and to enhance antibody potency and potentially efficacy. We developed a novel approach to generate and ascertain the functional attributes of Fc mutant monoclonal antibodies. This entailed coupling single expression vector (pVitro1) antibody cloning, using polymerase incomplete primer extension (PIPE) polymerase chain reaction, together with simultaneous Fc region point mutagenesis and high yield transient expression in human mammalian cells. Employing this, we engineered wild type, low (N297Q, NQ), and high (S239D/I332E, DE) FcR-binding Fc mutant monoclonal antibody panels recognizing two cancer antigens, HER2/neu and chondroitin sulfate proteoglycan 4. Antibodies were generated with universal mutagenic primers applicable to any IgG1 pVitro1 constructs, with high mutagenesis and transfection efficiency, in small culture volumes, at high yields and within 12 days from design to purified material. Antibody variants conserved their Fab-mediated recognition of target antigens and their direct anti-proliferative effects against cancer cells. Fc mutations had a significant impact on antibody interactions with Fc receptors (FcRs) on human NK cells, and consequently on the potency of NK cell activation, quantified by immune complex-mediated calcium mobilization and by antibody-dependent cellular cytotoxicity (ADCC) of tumor cells. This strategy for manipulation and testing of Fc region engagement with cognate FcRs can facilitate the design of antibodies with defined effector functions and potentially enhanced efficacy against tumor cells.

KW - ADCC

KW - Antibodies

KW - Cancer immunotherapy

KW - Chondroitin sulfate proteoglycan 4

KW - Cloning

KW - Expression

KW - HER2

KW - Mutants

UR - http://www.scopus.com/inward/record.url?scp=85029216942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029216942&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2017.01112

DO - 10.3389/fimmu.2017.01112

M3 - Article

AN - SCOPUS:85029216942

VL - 8

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - SEP

M1 - 1112

ER -